

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/888,824	06/25/2001	Eric Perrier	11123.24US01	9749	
23552 7:	590 09/26/2002				
MERCHANT & GOULD PC			EXAMI	EXAMINER	
P.O. BOX 2903 MINNEAPOLI	3 IS, MN 55402-0903		WEBER, JON P		
			ART UNIT	PAPER NUMBER	
			1651	~	
			DATE MAILED: 09/26/2002	1	

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicati	n N .	Applicant(s)			
Office Action Summary		09/888,824	1	PERRIER ET AL.			
		Examin r		Art Unit			
		Jon P. Web		1651			
The MAILING DATE of this c mmunication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status 1)□	Responsive to communication(s) filed on						
¹)∟ 2a)[]	, , , , , , , , , , , , , , , , , , , ,	— · iis action is r	on final				
·	,—			accoution on to the morite is			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims						
4)⊠ Claim(s) <u>1-43</u> is/are pending in the application.							
4	4a) Of the above claim(s) is/are withdrav	wn from con	sideration.				
5)	5) Claim(s) is/are allowed.						
6)□	Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
•	Claim(s) <u>1-43</u> are subject to restriction and/or e	election requ	uirement.	•			
Application Papers							
9) The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) □ approved b) □ disapproved by the Examiner. If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120 13) △ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No.							
2. Certified copies of the priority documents have been received in Application No3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)			(PTO-413) Paper No(s) atent Application (PTO-152)			

Application/Control Number: 09/888,824

Art Unit: 1651

Status of the Claims

Claims 1-43 have been presented for examination.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- Claims 1-24, drawn to a method for screening for inhibitors of lipoprotein lipase, classified in class 435, subclass 197.
- II. Claim 25, 30-43, drawn to plant extract containing lipoprotein lipase inhibitor or a lipolytic substance, classified, for example, in class 424, subclass 725+.
- III. Claims 26-29, drawn to methods of treating skin or disorders associated with fatty deposits with a plant extract containing lipoprotein lipase inhibitor, classified, for example, in class 424, subclass 730 and 775.

The inventions are distinct, each from the other because of the following reasons:

Inventions II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product could be used or enhancing immune, anti-inflammatory, anti-tumor and DNA repair processes of warm blooded animals (see for example, US 6361805).

Inventions I and III are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different

Application/Control Number: 09/888,824

Art Unit: 1651

functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions the screening assay does not use the any of the steps of the therapeutic method.

Compounds identified by the screen could be used in many treatment methods. Many compounds alleged to be active in the claimed therapy are known in the art.

Claims 25-43 generic to a plurality of disclosed patentably distinct species comprising a) plant extracts and b) lipolytic agents. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species if either of Groups II or III is elected, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1651

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jon P. Weber, Ph.D. whose telephone number is 703-308-4015. The examiner can normally be reached on daily, off 1st Fri, 9/5/4.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Wityshyn can be reached on 703-308-4743. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Jon P. Weber, Ph.D. Primary Examiner Art Unit 1651

JPW September 24, 2002